FDA clears Alzheimer’s blood test for symptomatic adults 40 and older

FDA opens a new front in Alzheimer’s testing

The US Food and Drug Administration has cleared C2N Diagnostics’ PrecivityAD2 blood test for patients aged 40 and older who show possible cognitive symptoms of Alzheimer’s disease, according to the source material provided. The clearance is notable not just because it expands access to blood-based testing, but because it does so for a younger group than previous FDA-cleared options. The source describes it as the first FDA-cleared blood test for Alzheimer’s in people this young.

That matters because Alzheimer’s pathology is widely understood to begin years before symptoms become obvious. In practice, clinicians and patients have often faced a narrow set of diagnostic routes: advanced imaging, cerebrospinal fluid analysis through lumbar puncture, or observation over time as symptoms progress. A blood test does not replace the broader clinical process, but it can alter how quickly that process moves and how early it begins.

PrecivityAD2 is intended for people who are already showing signs of possible cognitive decline. The supplied source explicitly says it is not meant to be used as a general screening tool. That distinction is central. The test is aimed at clarifying diagnosis in a clinical setting, not at broadly surveying healthy people for future risk.

What the test measures

According to the source text, PrecivityAD2 is a single blood test that evaluates the proteins amyloid and tau. It uses mass spectrometry to measure plasma Aβ42/40 and p-tau217/np-tau217, then produces a result categorized as negative, likely positive, or positive for Alzheimer’s disease. In other words, the test is built around biomarkers that are already central to current Alzheimer’s research and diagnosis.

The importance of that approach is that it attempts to bring a more specialized biological assessment into a much simpler sample collection method. Instead of requiring a brain scan or spinal fluid draw, clinicians can work from blood. For patients, that could lower the barrier to getting evaluated after symptoms appear. For providers, it could create a more practical triage point before moving to more invasive or expensive follow-up testing.

The source also says the test is based on technology developed by scientists at Washington University School of Medicine and notes that WashU Medicine’s Randall Bateman is a co-founder of C2N Diagnostics. That connection underscores how translational Alzheimer’s research is moving from academic biomarker work into commercial clinical tools.

Validation results and why they stand out

The supplied report cites a recent clinical validation study involving 1,142 symptomatic adults. In that study, PrecivityAD2 accurately identified 97.6% of positive biomarkers. It also reportedly delivered consistent results in patients with comorbidities including chronic kidney disease and diabetes, conditions the source says can distort plasma amyloid samples.

Those details are important because blood-based biomarker testing for neurodegenerative disease has to prove two things at once: that it can identify the relevant signals, and that it can do so in the messier reality of everyday medicine. Patients being evaluated for memory problems are often older, medically complex, and taking multiple medications. A test that only performs well in tightly controlled populations would have limited practical impact. The source’s emphasis on performance in people with common comorbidities suggests the field is moving beyond proof of concept and into questions of routine care.

Still, the information supplied does not present the test as a standalone diagnosis. Instead, it points to a tool that can support earlier detection and sharpen patient selection for care pathways and research. That is a meaningful distinction in a disease area where timing and diagnostic confidence increasingly matter.

Why timing matters in Alzheimer’s care

The source frames the approval as part of a rapidly changing diagnostic landscape. Just over a year earlier, it says, there were no FDA-cleared blood tests for Alzheimer’s. Now there are three. That pace signals a clear shift in the field: blood biomarkers are moving from experimental promise into regulated clinical use.

Earlier and easier testing could have downstream effects across the Alzheimer’s ecosystem. For clinicians, it may help determine whether a patient’s symptoms warrant further biomarker confirmation or specialist referral. For researchers, it could improve trial enrollment by identifying appropriate participants more efficiently. For health systems, it could eventually reduce dependence on narrower and more resource-intensive diagnostic channels.

The source also points to the larger epidemiological backdrop. The Alzheimer’s Association estimates that 7.4 million Americans aged 65 and older are living with Alzheimer’s disease, while about 200,000 have younger-onset disease. A test cleared for symptomatic adults starting at age 40 directly touches that second group, where diagnosis can be especially difficult because dementia is often not the first explanation considered.

That does not mean a blood test solves the problem of underdiagnosis on its own. But it may change the threshold for acting when symptoms emerge earlier in life.

From biomarker science to clinical practice

The broader significance of this clearance is not only the product itself, but what it says about the state of Alzheimer’s medicine. Biomarker-based approaches are becoming more practical, more regulated, and more integrated into care decisions. The supplied source quotes Alzheimer’s Drug Discovery Foundation CEO Isobel Coleman describing the emergence of multiple FDA-cleared blood tests as evidence that sustained early investment in translational science can move promising ideas from the lab to patients.

That framing is useful because it captures the transition now underway. Alzheimer’s testing is no longer defined solely by specialist imaging and invasive procedures. It is beginning to include tools that can fit more naturally into normal clinical workflows, while still relying on molecular signals tied to the disease process.

For patients with symptoms, the immediate value is potentially faster clarity. For the field, the larger outcome may be a more scalable way to connect diagnosis, trials, and eventually precision treatment strategies. The source stops short of claiming that blood testing alone will transform care. But it makes a strong case that the FDA’s latest clearance marks another concrete step toward earlier, more accessible Alzheimer’s evaluation.

• The FDA cleared C2N Diagnostics’ PrecivityAD2 for symptomatic patients aged 40 and older.
• The blood test measures amyloid and tau biomarkers using mass spectrometry.
• A validation study cited in the source involved 1,142 symptomatic adults and reported 97.6% identification of positive biomarkers.
• The source says the test is not intended for general population screening.

This article is based on reporting by New Atlas. Read the original article.